摘要
目的评估实时定量RT-PCR技术检测白血病融合基因在辅助白血病临床诊断和药物疗效判定方面的价值。方法56例慢性粒细胞白血病(CML)患者,其中男性31例,女性25例,中位年龄54(18～80)岁;9例急性早幼粒细胞白血病(APL)患者,其中男性4例,女性5例,中位年龄47(2～64)岁。另有22例非CML或APL患者(男性12例,女性10例,年龄6～55岁)。应用实时定量RT-PCR技术检测临床患者骨髓或外周血单个核细胞中白血病融合基因M-bcr/abl或PML/RARα的表达,结合临床资料进行分析。结果①56例CML患者的M-bcr/abl融合基因检测阳性率为96.4%(54/56);9例APL患者的PML/RARα融合基因检测阳性率为77.8%(7/9)。②5例CML患者应用甲磺酸-伊马替尼治疗后定量检测M-bcr/abl融合基因的拷贝数较治疗前明显降低或转阴(4/5),伊马替尼治疗CML效果优于应用羟基脲和干扰素治疗的患者。结论实时定量RT-PCR技术操作简便,检测白血病融合基因的准确性高,在辅助临床诊断和白血病患者药物疗效判定方面都有较大的应用价值。
Objective To evaluate the clinical value of real-time quantitative RT-PCR （RQ RT-PCR） approach detection for leukemic fusion genes in assisting diagnosis as well as monitoring the therapeutic effect. Methods Fifty-six patients with chronic myeloid leukemia （CML） （male 31 ,female 25 ,median age 54 years,aged 18 ～ 80 years） and 9 patients with acute promyelocytic leukemia （APL） （male 4, female 5, median age 47 years, aged 2 ～ 64 years） were enrolled. Besides, there were 22 patients with non-CML or non-APL （male 12,female 10,aged 6 ～ 55 7years）. The expressions of M-bcr/abl or PML/RARα transcripts in bone marrow or peripheral blood mononuclear cells from patients were detected by RQ RT-PCR approach. The outcomes were analyzed with provided patients＇ clinical data systemically. Results ①The M-bcr/abltranscriptweredetectedin54 （96.4 %） of 56 chronic myeloid leukemia（CML） cases, The PML/RARα transcript were detected in 7 （77.8 %） of 9 acute promyelocytic leukemia（APL） cases. ②The M-bcr/abl transcript was quantitatively decreased or un-detected in 5 CML cases received imatinib mesylate treatment,the effect of imatlnib was superior to interferon or chemotherapy in other CML cases. Conclusion The RQ RT-PCR detecting leukemic fusion genes is a simple, convenient and reliable approach,and has an important application value in assisting diagnosis and monitoring therapeutic effectiveness.
出处
《生物医学工程与临床》
CAS
2008年第1期71-74,共4页
Biomedical Engineering and Clinical Medicine
